---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

Cytovale

🌎 cytovale.com

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Their FDA cleared IntelliSep test analyzes white blood cells to stratify a patient’s risk of sepsis in under 10 minutes, addressing the urgent need for early detection of this lethal condition.

---

Cytovale - Latest News and Updates

• Cytovale's IntelliSep is the first and only FDA-cleared cellular host diagnostic for use in the emergency department.
• Cytovale's rapid lab test for sepsis, IntelliSep, has been cleared by the US FDA and reported to reduce sepsis mortality by over 30%.
• Cytovale has acquired Sepsis Scout, a company using wearable technology and AI to predict and prevent sepsis outside of hospitals.
• Cytovale's $100M Series D funding was highlighted on the Nasdaq Tower in Times Square.
• Cytovale, co-founded by UCLA's Dino Di Carlo and Henry Tse, has raised $100M for the hospital rollout of its FDA-cleared early sepsis-detection tool IntelliSep.

• Wilson Sonsini, led by Matt Bresnahan, advised Cytovale on IP matters for their $100 million Series D financing.
• Cytovale will showcase their IntelliSep sepsis test at CHEST2024, Booth 1252.
• Hannah Tarling has joined Cytovale as Customer Service and Commercial Order Lead in the United States, previously serving as Sr. Customer Service Operations Specialist at Outset Medical, Inc.
• Jeff Smith has left Cytovale, where he served as Sr Manager, Consumables R&D in the United States, to join Overture Life as Associate Director of Engineering.
• Matt G Sorrells is a Clinical Data Research Engineer at Cytovale.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.